Compare
Precision Biosciences Inc vs X4 Pharmaceuticals, Inc vs C4 Therapeutics, Inc. vs Scilex Holding Co
| Latest fiscal year | Precision Biosciences Inc DTIL | X4 Pharmaceuticals, Inc XFOR | C4 Therapeutics, Inc. CCCC | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $34.26M | $35.11M | $35.95M | $30.25M |
| Revenue growth (YoY) | -50.1% | n/m | +1.0% | -46.5% |
| Gross margin | n/a | 83.6% (computed) | n/a | 65.0% (computed) |
| Operating margin | -152.2% | -247.4% | -320.5% | n/m |
| Net margin | -133.4% | -225.6% | -292.1% | n/m |
| Net income | -$45.72M | -$79.20M | -$104.99M | -$374.05M |
| EPS (Diluted) | -$3.56 | -$1.87 | -$1.27 | -$36.48 |
| Operating cash flow | -$65.84M | -$85.62M | -$98.69M | $3.82M |
| Free cash flow | -$65.93M | -$85.62M | -$99.30M | $3.68M |
| Cash & equivalents | $110.82M | $217.05M | $74.60M | $4.96M |
| Total assets | $154.42M | $290.46M | $359.07M | $364.98M |
| Total liabilities | $62.17M | $104.17M | $102.49M | $576.73M |
| Shareholders' equity | $92.25M | $186.29M | $256.59M | -$207.78M |
| Return on year-end equity | -49.6% | -42.5% | -40.9% | n/a |
| Shares outstanding | 24.09M | 90.91M | 96.91M | 7.03M |
Revenue, most recent five fiscal years
| Fiscal year | Precision Biosciences Inc | X4 Pharmaceuticals, Inc | C4 Therapeutics, Inc. | Scilex Holding Co |
|---|---|---|---|---|
| Latest | $34.26M Ended 2025-12-31 | $35.11M Ended 2025-12-31 | $35.95M Ended 2025-12-31 | n/a |
| 1 year earlier | $68.70M Ended 2024-12-31 | $2.56M Ended 2024-12-31 | $35.58M Ended 2024-12-31 | n/a |
| 2 years earlier | $48.73M Ended 2023-12-31 | $0 Ended 2023-12-31 | $20.76M Ended 2023-12-31 | n/a |
| 3 years earlier | $25.10M Ended 2022-12-31 | $0 Ended 2022-12-31 | $31.10M Ended 2022-12-31 | n/a |
| 4 years earlier | $115.53M Ended 2021-12-31 | $0 Ended 2021-12-31 | $45.78M Ended 2021-12-31 | n/a |